General Lung Cancer

FDA Approves Keytruda® for Lung Cancer (10-13-2015)

The programmed death (PD-1) inhibitor Keytruda® (pembrolizumab) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the first PD-1 inhibitor and the second immunotherapy available for treatment of this... Continue Reading

Gilotrif Improves Outcomes in Lung Cancer (09-22-2015)

The targeted agent Gilotrif (afatinib) improves outcomes compared to Tarceva (erlotinib) among patients with squamous cell lung cancer. These results were recently published in The Lancet Oncology. Lung cancer remains the leading cause of cancer-related... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (08-10-2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (02-11-2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported... Continue Reading

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC (02-10-2015)

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However the... Continue Reading

Stereotactic Body Radiation Therapy Improves Survival in Stage IV Non Small Cell Lung Cancer and Represents New Treatment Option (01-21-2015)

The results of a recent clinical trial published in the Journal of Clinical Oncology in patients with stage IV non small cell lung caner (NSCLC) suggest that combining stereotactic body radiation therapy (SBRT) with Tarceva (erlotinib) chemotherapy significantly... Continue Reading

Non-Small Cell Lung Cancer: The ALCHEMIST Lung Cancer Trials (01-14-2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Advanced Squamous Cell Lung Cancer: The Lung-MAP Trial (01-13-2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Innovative Clinical Trials for Lung Cancer Currently Underway (01-12-2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer (01-8-2015)

The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues... Continue Reading

« Previous PageNext Page »